Clinical Trial Update: Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating limertinib in combination with radiotherapy for EGFR-mutant non-small cell lung cancer with brain metastases; the study is n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Limertinib (Limertinib)

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: NSCLC | Phase 2 | Status: NOT_YET_RECRUITING